CAR T Cell Toxicity: Current Management and Future Directions

Keywords

Lymphoma, Follicular lymphoma, Chimeric antigen receptor, Medicine, Oncology

References

• Fast Cars and No Brakes: Autologous Stem Cell Transplantation as a Platform for Novel ImmunotherapiesMiguel‐Angel Perales, Craig S. Sauter, Philippe Armand — 2015
• Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19.James N. Kochenderfer, Wyndham H. Wilson, John E. Janik — 2010
• The influence of cytokines on the integrity of the blood-brain barrier in vitro.Helga E. de Vries, Margret C.M. Blom-Roosemalen, Marijke van Oosten — 1996
• Managing Cytokine Release Syndrome Associated With Novel T Cell-Engaging TherapiesShannon L. Maude, David M. Barrett, David T. Teachey — 2014
• Astrocyte–endothelial interactions at the blood–brain barrierN. Joan Abbott, Lars Rönnbäck, Elisabeth Hansson — 2006
• Effect of dimethylsulfoxide on the functions of mesenchymal and hemopoietic precursorsG. N. Zyuz’kov, L. A. Gur’yantseva, Е. В. Симанина — 2007
• CD19 CAR-Targeted T Cells Induce Long-Term Remission and B Cell Aplasia in an Immunocompetent Mouse Model of B Cell Acute Lymphoblastic LeukemiaMarco L. Davila, Christopher C. Kloss, Gertrude Gunset — 2013
• Graft-versus-Host DiseaseJames L.M. Ferrara, John E. Levine, Pavan Reddy — 2009
• Exploring the full spectrum of macrophage activationDavid M. Mosser, Justin P. Edwards — 2008
• Angiopoietin-1 reduces cerebral blood vessel leakage and ischemic lesion volume after focal cerebral embolic ischemia in mice.Z.G Zhang, L Zhang, Susan D. Croll — 2002
• Current concepts in the diagnosis and management of cytokine release syndrome.Daniel W. Lee, Rebecca Gardner, David Porter — 2014
• Increased angiopoietin2 expression is associated with endothelial apoptosis and blood–brain barrier breakdownSukriti Nag, Tripti Papneja, Roopa Venugopalan — 2005
• Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic LeukemiaMarco L. Davila, Isabelle Rivière, Xiuyan Wang — 2014
• Chimeric Antigen Receptor T Cells for Sustained Remissions in LeukemiaShannon L. Maude, Noelle V. Frey, Pamela A. Shaw — 2014
• Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid LeukemiaDavid L. Porter, Bruce L. Levine, Michael Kalos — 2011
• Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemiaDavid Porter, Wei‐Ting Hwang, Noelle V. Frey — 2015
• Tumor lysis syndrome in the era of novel and targeted agents in patients with hematologic malignancies: a systematic reviewScott C. Howard, Steven Trifilio, Tara Gregory — 2016
• Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease.Jennifer N. Brudno, Robert Somerville, Victoria Shi — 2016
• Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia.Joseph A. Fraietta, Kyle A. Beckwith, Prachi Patel — 2016
• Toxicity and management in CAR T-cell therapyChallice L. Bonifant, Hollie J. Jackson, Renier J. Brentjens — 2016

Cited by

• Chimeric Antigen Receptor (CAR) T-Cell Therapy.John M. Pagel, Howard West — 2017
• Polyampholytes as Emerging Macromolecular CryoprotectantsChristopher D. Stubbs, Trisha L. Bailey, Kathryn A. Murray — 2019
• Recent Advances in CAR-T Cell Therapy for Non-Hodgkin Lymphoma.Avyakta Kallam, Julie M. Vose — 2019
• The Role of Autologous Stem Cell Transplantation in the Treatment of Diffuse Large B-cell Lymphoma in the Era of CAR-T Cell TherapyLazaros J. Lekakis, Craig H. Moskowitz — 2019
• Engineering T cells for immunotherapy of primary human hepatocellular carcinomaLeidy D. Caraballo Galva, Lun Cai, Yanxia Shao — 2020
• CAR T-Cell-Associated NeurotoxicityAmanda Rivera, Scott May, Matthew Lei — 2020
• Acute Kidney Injury after CAR-T Cell Therapy: Low Incidence and Rapid RecoveryVictoria Gutgarts, Tania Jain, Junting Zheng — 2020
• Myeloma CAR-T CRS Management With IL-1R Antagonist AnakinraShashi Jatiani, Adolfo Aleman, Deepu Madduri — 2020
• Expanding Access to Chimeric Antigen Receptor T-Cell Therapies: Challenges and Opportunities.Ankit Kansagra, Stephanie Farnia, Navneet S. Majhail — 2020
• The Advent of CAR T-Cell Therapy for Lymphoproliferative Neoplasms: Integrating Research Into Clinical PracticeMarco Cerrano, Marco Ruella, Miguel‐Angel Perales — 2020
• Nursing Management in CAR-T Cell TherapyKadriye Sayın Kasar, Yasemin Yıldırım — 2020
• Advances in Anti-Cancer Immunotherapy: Car-T Cell, Checkpoint Inhibitors, Dendritic Cell Vaccines, and Oncolytic Viruses, and Emerging Cellular and Molecular TargetsEmilie Alard, Aura-Bianca Butnariu, Marta Grillo — 2020
• Mechanogenetics for Cellular Engineering and Cancer ImmunotherapyLinshan Zhu, Yiqian Wu, Chi Woo Yoon — 2020
• CAR T-Cells in Multiple Myeloma: State of the Art and Future DirectionsLuis Gerardo Rodríguez‐Lobato, Maya Ganzetti, Carlos Fernández de Larrea — 2020
• A comprehensive review on: Chimeric Antigen Receptor (CAR) T-cell therapy in cancer treatmentBikash Pal, Bornika Chattaraj, Purnima Agrawal — 2020
• Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphomaKitsada Wudhikarn, M. Lia Palomba, Martina Pennisi — 2020
• The magic bullet as cancer therapeutic—has nanotechnology failed to find its mark?Gordon M. Xiong, Kailash Venkatraman, Subbu S. Venkatraman — 2020
• Neurotoxicity and Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy: Insights Into Mechanisms and Novel TherapiesElizabeth L. Siegler, Saad S. Kenderian — 2020
• Targeting FcRn for immunomodulation: Benefits, risks, and practical considerationsHans‐Hartmut Peter, Hans D. Ochs, Charlotte Cunningham‐Rundles — 2020
• Tisagenlecleucel in Children and Young Adults: Reverse Translational Research by Using Real-World Safety DataConcetta Rafaniello, Carmen Ferrajolo, Mario Gaio — 2020

Related papers

• You Have Got a Fast CAR: Chimeric Antigen Receptor NK Cells in Cancer TherapyAline Pfefferle, Nicholas D. Huntington — 2020
• Expression of microRNAs in diffuse large B cell lymphoma is associated with immunophenotype, survival and transformation from follicular lymphomaCharles H. Lawrie, Jianxiang Chi, Stephen Taylor — 2008
• Efficacy of Chimeric Antigen Receptor (CAR) T-Cell Therapy, Axicabtagene Ciloleucel (axi-cel), in Patients with Refractory Large B-Cell Lymphoma (LBCL)Sairah Ahmed, Paolo Strati, Luis Fayad — 2021
• Composite lymphoma of the axillary lymph node comprising peripheral T-cell lymphoma-not otherwise specified and follicular B-cell lymphoma: A case reportSandhya Kolagatla, Joshua K. Jenkins, Zainab Fatima — 2022
• Anti-CD20 monoclonal antibody therapy for the patients with cutaneous B-cell lymphomaTakahiro Kiyohara — 2004
• Large-cell transformation of a composite lymphoma.Guy diSibio, E. Peter Gabor, Jean Lopategui — 2010
• Frequency of bcl-2 gene rearrangement in B-cell Non-Hodgkin's lymphoma.Adeel Arif, Shahid Jamal, Sajid Mushtaq — 2009
• High-grade B-cell Lymphoma with MYC and BCL2 Rearrangement Arising from Follicular Lymphoma: Presentation as a Large Peripancreatic MassAnna Shestakova, Sherif Rezk, Dara Ghasemizadeh — 2020
• Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphomaQing Ye, Zijun Y. Xu‐Monette, Alexandar Tzankov — 2015